Hanmi Pharma (128940.KS) Q1 2026: R&D at 16.6% Narrows Operating Profit 9%
*Beijing Hanmi's 22% segment margin and ₩93 billion in free cash flow cushion a quarter where accelerated R&D spending — not operational weakness — produced the year-on-year earnings shortfall.*
Source: Quarterly Report (Q1 FY2026, 17th Fiscal Year) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
“Hanmi Pharma (128940.KS) Q1 2026: R&D at 16.6% Narrows Operating Profit 9%”
This article became available on June 19, 2026. Subscribe to read in full, or wait until September 17, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
Access is tied to your account. Subscribe with the same email you sign up with — if you already paid, sign up with that email and it unlocks automatically.
You just read what happened. Here's how to read what it means.
LineVest Daily lands in your inbox before every opening bell: the key U.S. markets stories, earnings, disclosures and foreign flows — in plain English. Free, no card required.
We read Hanmi Pharma's latest SEC filing in full — financials under US GAAP, governance, and what it means for the stock. PDF in your inbox within 3 hours.
$12 · one-time
Get the Hanmi Pharma reportReading several U.S. stocks a week? Read every analysis article the moment it publishes — full daily U.S. market coverage plus the 90-day archive.
$9.99 · monthly
SubscribeIndependent journalism based on primary SEC filings — not investment advice. No brokerage affiliation.
